Cholesterol and the cerebral circulation

Future Lipidology

Volumn 2, Issue 2, 2007, Pages 211-228

  Magyar, Mária Tünde ^a   Bereczki, Dániel ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Atherosclerosis; Carotid artery; Cerebrovascular reactivity; Cholesterol; Intima media thickness; Lacunar infarcts; Leukoaraiosis; Microbleeds; Stroke; Transcranial Doppler; Ultrasound

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; ATORVASTATIN; CERIVASTATIN; CHOLESTEROL; COLESTIPOL; DYDROGESTERONE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ESTRADIOL; EZETIMIBE; FIBRIC ACID DERIVATIVE; FOSINOPRIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; NITRIC OXIDE; PLACEBO; PRAVASTATIN; PROBUCOL; ROSUVASTATIN; SIMVASTATIN; TORCETRAPIB; TRIACYLGLYCEROL;

ADD ON THERAPY; AGE; ANGIOGRAPHY; APHERESIS; ARTERY INTIMA PROLIFERATION; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; AUSCULTATION; BLOOD VESSEL REACTIVITY; BRAIN ATHEROSCLEROSIS; BRAIN HEMORRHAGE; BRAIN INFARCTION; CARDIOVASCULAR DISEASE; CAROTID ARTERY DISEASE; CAROTID ARTERY OBSTRUCTION; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMMON CAROTID ARTERY; COMPUTER ASSISTED TOMOGRAPHY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIET THERAPY; DISEASE SEVERITY; DOPPLER ECHOGRAPHY; DRUG MEGADOSE; FAMILIAL HYPERCHOLESTEROLEMIA; FAMILY HISTORY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HEREDITY; HISTOPATHOLOGY; HORMONE SUBSTITUTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INFLAMMATION; INTERMETHOD COMPARISON; ISCHEMIC HEART DISEASE; LEUKOARAIOSIS; LEUKOCYTE COUNT; LIPID BLOOD LEVEL; MAGNETIC RESONANCE ANGIOGRAPHY; MONOTHERAPY; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 34249297969     PISSN: 17460875     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460875.2.2.211     Document Type: Review

References (132)

1. Thomas HE Jr, Kannel WB, Dawber TR, McNamara PM: Cholesterol-phospholipid ratio in the prediction of coronary heart disease. The Framingham study. N. Engl. J. Med. 274, 701-705 (1966).
2. Adolfsson R, Svardsudd K, Tibblin G: 1913 men study - a longitudinal study of the development of stroke in a population. Scand. J. Soc. Med. Suppl. 14, 122-127 (1977).
3. Iso H, Jacobs DR Jr, Wentworth D, Neaton JD, Cohen JD: Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N. Engl. J. Med. 320, 904-910 (1989).
4. Hachinski V, Graffagnino C, Beaudry M et al.: Lipids and stroke: a paradox resolved. Arch. Neurol. 53, 303-308 (1996).
5. Collins R, Armitage J, Parish S, Sleight P, Peto R: Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 363(9411), 757-767 (2004).
6. Amarenco P, Bogousslavsky J, Callahan A 3rd et al.: Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N. Engl. J. Med. 355, 549-559 (2006).
7. Lastilla M: Lacunar infarct. Clin. Exp. Hypertens. 28, 205-215 (2006).
8. Heistad DD, Kontos HA: Cerebral circulation. In: Handbook of Physiology. Shepherd JT, Abbound FM (Eds). American Physiological Society, Washington, DC, USA 137-182 (1983).
9. Bots ML, Grobbee DE: Intima media thickness as a surrogate marker for generalised atherosclerosis. Cardiovasc. Drugs Ther. 16, 341-351 (2002).
10. Spence JD, Hegele RA: Noninvasive phenotypes of atherosclerosis: similar windows but different views. Stroke 35, 649-653 (2004).
11. Junyent M, Cofan M, Nunez I, Gilabert R. Zambon D. Ros F.: Influence of HDL cholesterol on preclinical carotid atherosclerosis in familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 26, 1107-1113 (2006).
12. Ford CS, Crouse JR 3rd, Howard G, Toole JF, Ball MR, Frye J: The role of plasma lipids in carotid bifurcation atherosclerosis. Ann. Neurol. 17, 301-303 (1985).
13. Homer D, Ingall TJ, Baker HL Jr, O'Fallon WM, Kottke BA, Whisnant JP: Serum lipids and lipoproteins are less powerful predictors of extracranial carotid artery atherosclerosis than are cigarette smoking and hypertension. Mayo Clin. Proc. 66, 259-267 (1991).
14. Salonen R, Seppanen K, Rauramaa R, Salonen JT. Prevalence of carotid atherosclerosis and serum cholesterol levels in eastern Finland. Arteriosclerosis 8, 788-792 (1988).
15. O'Leary DH, Anderson KM, Wolf PA, Evans JC, Poehlman HW. Cholesterol and carotid atherosclerosis in older persons: the Framingham Study. Ann. Epidemiol. 2, 147-153 (1992).
16. Wilson PW, Hoeg JM, D'Agostino RB et al.: Cumulative effects of high cholesterol levels, high blood pressure, and cigarette smoking on carotid stenosis. N. Engl. J. Med. 337, 516-522 (1997).
17. Sharrett AR, Patsch W. Sorlie PD, Heiss G, Bond MG, Davis CE: Associations of lipoprotein cholesterols, apolipoproteins A-I and B. and triglycerides with carotid atherosclerosis and coronary heart disease. The Atherosclerosis Risk in Communities (ARIC) Study. Arteriosler. Thromb. 14, 1098-1104 (1994).
18. Ma J, Folsom AR, Lewis L, Eckfeldt JH: Relation of plasma phospholipid and cholesterol ester fatty acid composition to carotid artery intima - media thickness: the Atherosclerosis Risk in Communities (ARIC) Study. Am. J. Clin. Nuir. 65, 551-559 (1997).
19. Johnsen SH. Mathiesen EB. Fosse E et al.: Elevated high-density lipoprotein cholesterol levels are protective against plaque progression: a follow-up study of 1952 persons with carotid atherosclerosis. The Tromso study. Circulation 112, 498-504 (2005).
20. Montalcini T, Gorgone G, Federico D et al.: Association of LDL cholesterol with carotid atherosclerosis in menopausal women affected by the metabolic syndrome. Nutr. Metab. Cardiovasc. Dis. 15. 368-372 (2005).
21. Kawamoto R, Tomita H, Oka Y, Kodama A, Kamitani A: Metabolic syndrome amplifies the LDL-cholesterol associated increases in carotid atherosclerosis. Intern. Med. 44, 1232-1238 (2005).
22. Virkola K. Pesonen E, Akerblom HK, Siimes MA: Cholesterol and carotid artery wall in children and adolescents with familial hypercholesterolaemia: a controlled study by ultrasound. Acta Paediatr. 86, 1203-1207 (1997).
23. Liuba P, Persson J, Luoma J. Yla-Herttuala S, Pesonen E: Acute infections in children are accompanied by oxidative modification of LDL and decrease of HDL cholesterol, and are followed by thickening of carotid intima-media. Eur. Heart J. 24, 515-521 (2003).
24. Magyar MT, Paragh G, Katona E et al.: Serum cholesterols have a more important role than triglycerides in determining intima - media thickness of the common carotid artery in subjects below 55 years of age. J. Ultrasound Med. 23, 1161-1169 (2004).
25. Kerenyi L, Mihalka L, Csiba L, Bacso H, Bereczki D: Role of hyperlipidemia in atherosclerotic plaque formation in the internal carotid artery. J. Clin. Ultrasound 34, 283-288 (2006).
26. Moskau S. Golla A, Grothe C, Boes M, Pohl C, Klockgether T: Heritability of carotid artery atherosclerotic lesions: an ultrasound study in 154 families. Stroke 36, 5-8 (2005).
27. Manolio, TA, Boerwinkle E, O'Donnell CJ, Wilson AF. Genetics of ultrasonographic carotid atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 24. 1567-1577 (2004).
28. Chen L, Patsch W, Boerwinkle E: HindIII DNA polymorphism in the lipoprotein lipase gene and plasma lipid phenotypes and carotid artery atherosclerosis. Hum. Genet. 98, 551-556 (1996).
29. Karvonen MK, Valkonen VP, Lakka TA et al.: Leucine7 to proline7 polymorphism in the preproneuropeptide Y is associated with the progression of carotid atherosclerosis, blood pressure and serum lipids in Finnish men. Atherosclerosis 159, 145-151 (2001).
30. Kakko S, Tamminen M, Paivansalo M et al.: Cholesteryl ester transfer protein gene polymorphisms are associated with carotid atherosclerosis in men. Eur. J. Clin. Invest. 30, 18-25 (2000).
31. Kakko S. Tamminen M, Palvansalo, M et al.: Variation at the cholesteryl ester transfer protein gene in relation to plasma high density lipoproteins cholesterol levels and carotid intima-media thickness. Eur. J. Clin. Invest. 31, 593-602 (2001).
32. Sposito AC, Gonbert S, Turpin G, Chapman MJ, Thillet J. Common promoter C516T polymorphism in the ApoB gene is an independent predictor of carotid atherosclerotic disease in subjects presenting a broad range of plasma cholesterol levels. Arterioscler. Thromb. Vasc. Biol. 24, 2192-2195 (2004).
33. Miller M, Rhyne J, Hong SH, Friel G, Dolinar C. Riley W: Do mutations causing low HDL-C promote increased carotid intima-media thickness? Clin. Chim. Acta 377, 273-275 (2007).
34. Benton JL, Ding J, Tsai MY et al.: Associations between two common polymorphisms in the ABCA1 gene and subclinical atherosclerosis: Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis (2007) (Epub ahead of print).
35. Volcik KA, Barkley RA, Hutchinson RG et al.: Apolipoprotein E polymorphisms predict low density lipoprotein cholesterol levels and carotid artery wall thickness but not incident coronary heart disease in 12,491 ARIC study participants. Am. J. Epidemiol. 164, 342-348 (2006).
36. Mathiesen EB, Bonaa KH, Joakimsen O: Low levels of high-density lipoprotein cholesterol are associated with echolucent carotid artery plaques: the Tromso study Stroke 32, 1960-1965 (2001).
37. Virgolini I, O'Grady J, Lupattelli G et al.: In vivo quantification of cholesterol content in human carotid arteries by quantitative gamma-camera imaging after injection of autologous low density lipoproteins (LDL). Int. J. Rad. Appl. Instrum B. 19, 245-250 (1992).
38. Forbat SM, Naoumova RP, Sidhu PS et al.: The effect of cholesterol reduction with fluvastatin on aortic compliance, coronary calcification and carotid intimal-medial thickness: a pilot study. J. Cardiovasc. Risk 5, 1-10 (1998).
39. Desai MY, Rodriguez A, Wasserman BA et al.: Association of cholesterol subfractions and carotid lipid core measured by MRI. Arterioscler. Thromb. Vasc. Biol. 25, E110-E111 (2005).
40. Nahrendorf M, Jaffer FA, Kelly KA et al.: Noninvasive vascular cell adhesion molecule-1 imaging identifies inflammatory activation of cells in atherosclerosis. Circulation 114, 1504-1511 (2006).
41. Ruberg FL, Viereck J, Phinikaridou A, Qiao Y, Loscalzo J, Hamilton JA: Identification of cholesteryl esters in human carotid atherosclerosis by ex vivo image-guided proton MRS. J. Lipid Res. 47, 310-317 (2006).
42. Miwa S, Inouye M, Ohmura C, Mitsuhashi N, Onuma T, Kawamori R: Relationship between carotid atherosclerosis and erythrocyte membrane cholesterol oxidation products in Type 2 diabetic patients. Diabetes Res. Clin. Pract. 61, 81-88 (2003).
43. Tzou WS, Mays ME, Korcarz CE, Aeschlimann SE, Stein JH: Skin cholesterol content identifies increased carotid intima-media thickness in asymptomatic adults. Am. Heart J. 150, 1135-1139 (2005).
44. Furberg CD, Adams HP Jr, Applegate WB et al.: Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation 90, 1679-1687 (1994).
45. Taylor AJ, Kent SM, Flaherty PJ, Coyle LC, Markwood TT, Vernalis MN: ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation 106, 2055-2060 (2002).
46. Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA: Arterial biology for the investigation of the treatment effects of reducing cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 110, 3512-3517 (2004).
47. Taylor AJ, Lee HJ, Sullenberger LE: The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr. Med. Res. Opin. 22, 2243-2250 (2006).
48. Salonen RM, Nyyssonen K, Kaikkonen J et al.: Antioxidant Supplementation in Atherosclerosis Prevention Study. Six-year effect of combined vitamin C and E supplementation on atherosclerotic progression: the Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) Study. Circulation 107, 947-953 (2003).
49. Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF: Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 357 (9256), 577-581 (2001).
50. Mercuri M, Bond MG, Sirtori CR et al.: Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study. Am. J. Med. 101, 627-346 (1996).
51. Simon T, Boutouyrie P, Gompel A et al.: CASHMERE investigators. Rationale, design and methods of the CASHMERE study. Fundam. Clin. Pharmacol. 18, 131-138 (2004).
52. Azen SP, Qian D, Mack WJ et al.: Effect of supplementary antioxidant vitamin intake on carotid arterial wall intima-media thickness in a controlled clinical trial of cholesterol. Circulation 94, 2369-2372 (1996).
53. Kastelein JJ, Sager PT, de Groot E, Veltri E: Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial. Am. Heart J. 149, 234-239 (2005).
54. Sawayama Y, Shimizu C, Maeda N et al.: Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka Atherosclerosis Trial (FAST). J. Am. Coll. Cardiol. 39, 610-661 (2002).
55. MacMahon S, Sharpe N, Gamble G et al.: Effects of lowering average of below-average cholesterol levels on the progression of carotid atherosclerosis: results of the LIPID Atherosclerosis Substudy. LIPID Trial Research Group. Circulation 97, 1784-1790 (1998).
56. Hodis HN, Mack WJ, Dunn M et al.: Intermediate-density lipoproteins and progression of carotid arterial wall intima-media thickness. Circulation 95, 2022-2026 (1997).
57. Crouse JR 3rd, Grobbee DE, O'Leary DH et al.: Measuring effects on intima-media thickness: an Evalution Of Rosuvastatin study group. Measuring Effects on intima-media Thickness: an Evaluation Of Rosuvastatin in subclinical atherosclerosis - the rationale and methodology of the METEOR study. Cardiovasc. Drugs Ther. 18, 231-238 (2004).
58. Zanchetti A, Crepaldi G, Bond MG et al.: PHYLLIS Investigators. Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis: principal results of PHYLLIS - a randomized double-blind trial. Stroke 35, 2807-2812 (2004).
59. Crouse JR, Byington RP, Bond MG et al.: Pravastatin, lipids, and atherosclerosis in the carotid arteries: design features of a clinical trial with carotid atherosclerosis outcome. Control. Clin. Trials 13, 495-506 (1992).
60. Byington RP, Furberg CD, Crouse JR 3rd, Espeland MA, Bond MG: Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II). Am. J. Cardiol. 76, C54-C59 (1995).
61. Wilt TJ, Rubins HB, Robins SJ et al.: Carotid atherosclerosis in men with low levels of HDL cholesterol. Stroke 28, 1919-1925 (1997).
62. Baldassarre D, Veglia F, Gobbi C et al.: Intima-media thickness after pravastatin stabilizes also in patients with moderate to no reduction in LDL-cholesterol levels: the Carotid Atherosclerosis Italian Ultrasound Study. Atherosclerosis 151, 575-583 (2000).
63. Kent SM, Coyle LC, Flaherty PJ, Markwood TT, Taylor AJ: Marked low-density lipoprotein cholesterol reduction below current national cholesterol education program targets provides the greatest reduction in carotid atherosclerosis. Clin. Cardiol. 27, 17-21 (2004).
64. Reid JA, Wolsley C. Lau LL et al.: The effect of pravastatin on intima media thickness of the carotid artery in patients with normal cholesterol. Eur. J. Vasc. Endovasc. Surg. 30, 464-468 (2005).
65. Kang S, Wu Y, Li X: Effects of statin therapy on the progression of carotid atherosclerosis: a systematic review and meta-analysis. Atherosclerosis 177, 433-442 (2004).
66. Agewall S, Fagerberg B, Berglund G, Schmidt C, Wendelhag I, Wikstrand J: Risk Factor Intervention Study Group, Sweden. Multiple risk intervention trial in high risk hypertensive men: comparison of ultrasound intima-media thickness and clinical outcome during 6 years of follow-up. J. Intern. Med. 249, 305-314 (2001).
67. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr: Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N. Engl. J. Med. 340, 14-22 (1999).
68. Touboul PJ, Vicaut E, Labreuche J et al.: On behalf of PARC study participating physicians. Correlation between the Framingham risk score and intima media thickness: The Paroi Arterielle et Risque Cardio-vasculaire (PARC) study. Atherosclerosis (2007) (Epub ahead of print).
69. Bots ML: Carotid intima-media thickness as a surrogate marker for cardiovascular disease in intervention studies. Curr. Med. Res. Opin. 22, 2181-2190 (2006).
70. Hennerici M, Kleophas W, Gries FA. Regression of carotid plaques during low density lipoprotein cholesterol elimination. Stroke 22, 989-892 (1991).
71. Kurata T, Kurata M, Okada T: Cerivastatin induces carotid artery plaque stabilization independently of cholesterol lowering in patients with hypercholesterolaemia. J. Int. Med. Res. 29, 329-334 (2001).
72. Yuan C, Kerwin WS, Yarnykh VL et al.: MRI of atherosclerosis in clinical trials. NMR Biomed. 19, 636-654 (2006).
73. Chironi G, Simon A, Gariepy J, Balice M, Del-Pino M, Levenson J: Differential associations of statin and fibrate treatment with carotid arterial remodeling. Am. J. Hypertens. 18, 1476-1481 (2005).
74. McKenney JM, Davidson MH, Shear CL, Revkin JH: Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin. J. Am. Coll. Cardiol. 48, 1782-1790 (2006).
75. Magliano D, McNeil J, Branley P et al.: The Melbourne Atherosclerosis Vitamin E Trial (MAVET): a study of high dose vitamin E in smokers. Eur. J. Cardiovasc. Prev. Rehabil. 13, 341-347 (2006).
76. Sawayama Y, Maeda S, Ohnishi H, Okada K, Hayashi J: Effect of probucol on elderly hypercholesterolemic patients in the FAST study. Fukuoka Igaku Zasshi 97, 15-24 (2006).
77. Homma Y, Mikami Y, Tamachi H et al.: Comparison of selectivity of LDL removal by double filtration and dextran-sulfate cellulose column plasmapheresis. Atherosclerosis 60, 23-27 (1986).
78. Krebs A, Krebs K, Keller F: Retrospective comparison of 5 different methods for long-term LDL-apheresis in 20 patients between 1986 and 2001. Int. J. Artif. Organs 27, 137-148 (2004).
79. Stegmayr B, Lalau JD, Johnson O: In face of the increasing efficacy of lipid-lowering therapy, is there still a place for LDL-apheresis? Transfus. Apher. Sci. 30, 213-220 (2004).
80. Seo DM, Goldschmidt-Clermont PJ: Unraveling the genetics of atherosclerosis: implications for diagnosis and treatment. Expert Rev. Mol. Diagn. 7, 45-51 (2007).
81. Nakajima Y, Iwatsuki K. Ishii K et al.: Medical application of an infrared free-electron laser: selective removal of cholesterol ester in carotid artery atheromatous plaques. J. Neurosurg. 104, 426-428 (2006).
82. de Jong G, Kessels F, Lodder J: Two types of lacunar infarcts: further arguments from a study on prognosis. Stroke 33, 2072-2076 (2002).
83. Amarenco P, Labreuche J, Elbaz A et al.: GENIC Investigators. Blood lipids in brain infarction subtypes. Cerebrovasc. Dis. 22, 101-108 (2006).
84. Laloux P, Galanti L, Jamart J: Lipids in ischemic stroke subtypes. Acta Neurol. Belg. 104, 13-19 (2004).
85. Adams RJ, Carroll RM, Nichols FT et al.: Plasma lipoproteins in cortical versus lacunar infarction. Stroke 20, 448-452 (1989).
86. Kawamoto A, Shimada K. Matsubayashi K, Nishinaga M, Kimura S, Ozawa T: Factors associated with silent multiple lacunar lesions on magnetic resonance imaging in asymptomatic elderly hypertensive patients. Clin. Exp. Pharmacol. Physiol. 18, 605-610 (1991).
87. Giroud M, Boutron MC, Gras P et al.: Plasma lipoproteins in cortical versus lacunar infarction with or without cardiac arrhythmia, and in transient ischaemic attacks: a case control study. Neurol. Res. 14, 315-320 (1992).
88. Pedro-Botet J, Senti M, Nogues X et al.: Lipoprotein and apolipoprotein profile in men with ischemic stroke. Role of lipoprotein(a), triglyceride-rich lipoproteins, and apolipoprotein E polymorphism. Stroke 23, 1556-1562 (1992).
89. Matz K, Tatschi C, Sebek K, Dachenhausen A, Brainin M: Dyslipidemia, elevated LDL cholesterol and reduced nocturnal blood pressure dipping denote lacunar strokes occurring during nighttime. Eur. J. Neurol. 11, 742-748 (2004).
90. Shintani S, Shiigai T, Arinami T: Silent lacunar infarction on magnetic resonance imaging (MRI): risk factors. J. Neurol. Sci. 160, 82-86 (1998).
91. Longstreth WT Jr, Arnold AM, Beauchamp NJ Jr et al.: Incidence, manifestations, and predictors of worsening white matter on serial cranial magnetic resonance imaging in the elderly: the Cardiovascular Health Study. Stroke 36, 56-61 (2005).
92. ten Dam VH, van den Heuvel DM, van Buchem MA et al.: Effect of pravastatin on cerebral infarcts and white matter lesions. Neurology 64, 1807-1809 (2005).
93. Tanaka A, Ueno Y, Nakayama Y, Takano K, Takebayashi S. Small chronic hemorrhages and ischemic lesions in association with spontaneous intracerebral hematomas. Stroke 30, 1637-1642 (1999).
94. Tirschwell DL, Smith NL, Heckbert SR, Lemaitre RN, Longstreth WT Jr, Psaty BM. Association of cholesterol with stroke risk varies in stroke subtypes and patient subgroups. Neurology 63, 1868-1875 (2004).
95. Grotta JC: Management of primary hypertensive hemorrhage of the brain. Curr. Treat. Options Neurol. 6, 435-442 (2004).
96. Fazekas F, Kleinert R, Roob G et al.: Histopathologic analysis of foci of signal loss on gradient-echo T2*-weighted MR images in patients with spontaneous intracerebral hemorrhage: evidence of microangiopathy-related microbleeds. Am. J. Neuroradiol. 20, 637-642 (1999).
97. Lee SH, Bae HJ, Yoon BW, Kim H, Kim DE, Rob JK: Low concentration of serum total cholesterol is associated with multifocal signal loss lesions on gradient-echo magnetic resonance imaging: analysis of risk factors for multifocal signal loss lesions. Stroke 33, 2845-2849 (2002).
98. Jeerakathil T, Wolf PA, Beiser A et al.: Cerebral microbleeds: prevalence and associations with cardiovascular risk factors in the Framingham Study. Stroke 35, 1831-1835 (2004).
99. Koennecke HC: Cerebral microbleeds on MRI: prevalence, associations, and potential clinical implications. Neurology 66, 165-171 (2006).
100. Chen YW, Gurol ME. Rosand J et al.: Progression of white matter lesions and hemorrhages in cerebral amyloid angiopathy. Neurology 67, 83-87 (2006).
101. Andresen J, Shafi NI, Bryan RM Jr: Endothelial influences on cerebrovascular tone. J. Appl. Physiol. 100, 318-327 (2006).
102. White RP, Deane C, Vallace P, Markus HS: Nitric oxide synthase inhibition in humans reduces cerebral blood flow but not the hyperemic response to hypercapnia. Stroke 29, 467-472 (1998).
103. White RP, Vallace P, Markus HS: Effect of inhibition of nitric oxide synthase on dynamic cerebral autoregulation in humans. Clin. Sci. 99, 555-560 (2000).
104. Garg UC, Hassid A: Nitric oxide-generating vasodilators and 8-bromocyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J. Clin. Invest. 83, 1774-1777 (1989).
105. Adams MR, Jessup W, Hailstones D, Celermajer DS: L-arginine reduces human monocyte adhesion to vascular endothelium and endothetial expression of cell adhesion molecules. Circulation 95, 662-668 (1997).
106. Cardillo C, Kilcoyne CM, Cannon RO 3rd, Panza JA: Interactions between nitric oxide and endothelin in the regulation of vascular tone of human resistance vessels in vivo. Hypertension 35, 1237-1241 (2000).
107. Nohria A, Garrett L, Johnson W, Kinlay S, Ganz P, Creager MA: Endothelin-1 and vascular tone in subjects with atherogenic risk factors. Hypertension 42, 43-48 (2003).
108. Sloan MA, Alexandrov AV, Tegeler CH et al.: Assessment: transcranial Doppler ultrasonography. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 62, 1468-1481 (2004).
109. Aaslid R, Markwalder TM, Nornes H: Noninvasive transcranial Doppler ultrasound recording of flow velocity in basal cerebral arteries. J. Neurosurg. 57, 769-774 (1982).
110. Markus HS, Harrison MJ: Estimation of cerebrovascular reactivity using transcranial Doppler, including the use of breath-holding as the vasodilatory stimulus. Stroke 23, 668-673 (1992).
111. Malatino LS, Bellofiore S, Costa MP, Lo Manto G, Finocchiaro F, Di Maria GU: Cerebral blood flow velocity after hyperventilation-induced vasoconstriction in hypertensive patients. Stroke 23, 1728-1732 (1992).
112. 2 reactivity, cholesterol, and high-density lipoprotein cholesterol in the elderly. Neurology 54, 987-989 (2000).
113. Kerényi LL, Fülesdi B, Ficzere A et al.: Cerebrovascular reserve capacity in patients with hyperlipidemia. J. Clin. Ultrasound 28, 115-121 (2000).
114. Pretnar-Oblak J, Sabovic M, Sebestjen M, Pogacnik T, Zaletel M: Influence of atorvastatin treatment on L-arginine cerebrovascular reactivity and flow-mediated dilatation in patients with lacunar infarctions. Stroke 37, 2540-2545 (2002).
115. Gur AY, Bova I, Bornstein NM: Is impaired cerebral vasomotor reactivity a predictive factor of stroke in asymptomatic patients? Stroke 27, 2188-2190 (1996).
116. Galle J, Busse R, Bassenge E: Hypercholesterolemia and atherosclerosis change vascular reactivity in rabbits by different mechanisms. Arterioscler. Thromb. 11, 1712-1718 (1991).
117. Rodriguez G, Bertolini S, Nobili F et al.: Regional cerebral blood flow in familial hypercholesterolemia. Stroke 25, 831-836 (1994).
118. 2 reactivity after heparin-mediated extracorporal LDL precipitation (HELP) in patients with coronary heart disease and hyperlipidemia. Stroke 30, 1802-1806 (1999).
119. Takahashi K, Ohyanagi M, Ikeoka K, Iwasaki T. Acetylcholine-induced response of coronary resistance arterioles in cholesterol-fed rabbits. Jpn J. Pharmacol. 81, 156-162 (1999).
120. Mathew V, Cannan CR, Miller VM et al.: Enhanced endothelin-mediated coronary vasoconstriction and attenuated basal nitric oxide activity in experimental hypercholesterolemia. Circulation 96, 1930-1936 (1997).
121. Stokes KY, Cooper D, Tailor A, Granger DN: Hypercholesterolemia promotes inflammation and microvascular dysfunction: role of nitric oxide and superoxide. Free Radic. Biol. Med. 33, 1026-1036 (2002).
122. Assmann G, Gotto AM Jr: HDL cholesterol and protective factors in atherosclerosis. Circulation 109(23 Suppl. 1), III8-III14 (2004).
123. Cardillo C, Kilcoyne CM, Cannon RO 3rd, Panza JA: Increased activity of endogenous endothelin in patients with hypercholesterolemia. J. Am. Coll. Cardiol. 36, 1483-1488 (2000).
124. Yuhanna, IS. Zhu Y, Cox BE et al.: High-density lipoprotein binding to scavanger receptor-BI activates endothelial nitric oxide synthase. Nat. Med. 7, 853-857 (2001).
125. Li XA, Titlow WB, Lackson BA et al.: High density lipoprotein binding to scavanger receptor, class B, type I activates endothelial nitric-oxide synthase in a ceramide-dependent manner. J. Biol. Chem. 277, 11058-11063 (2002).
126. Speiker LE, Sudano I, Hurlimann D et al.: High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation 105, 1399-1402 (2002).
127. Scandinavian Simvastatin Survival Study Group: Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 334, 1383-1389 (1994).
128. Amarenco P, Labreuche J, Lavallee P, Touboul PJ: Statin in stroke prevention and carotid atherosclerosis: systematic review and meta-analysis. Stroke 35, 2902-2909 (2004).
129. Amarenco P, Moskowitz MA: The dinamics of statins. From prevention to neuroprotection. Stroke, 294-296 (2006).
130. Sterzer P, Meintzschel F, Rösler A, Lanfermann H. Steinmetz H, Sitzer M: Pravastatin improves cerebral vasomotor reactivity in patients with subcortical small vesseldisease. Stroke 32, 2817-2820(2001).
131. Pretnar-Oblak J, Sabovic M, Sebestjen M, Pogacnik T, Zaletel M: Influence of atorvastatin treatment on L-arginine cerebrovascular reactivity and flow-mediated dilatation in patient swith lacunar infarctions. Stroke 37, 2540-2545 (2006).
132. Carod-Artal FJ: Statins and cerebral vasomotor reactivity: implications for a new therapy? Stroke 37, 2446-2448 (2006).